Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > April 4, 2023
Daily News
April 4, 2023
- Silgard 9 Now Available under NIP; MSD Renews Call for Cervical Cancer Prevention
April 4, 2023
- Insmed Taps Ex-Gilead Director Makoto Nakamura as New Japan Chief
April 4, 2023
- Yoshihiro Toyohara to Lead Teva Takeda from June
April 4, 2023
- Eisai to Offer Tazverik for NCC’s Patient-Proposed Study
April 4, 2023
- 19 of 41 Drug Makers Log P/B Ratio Below 1; TSE’s Quest to Boost Market Cap Not Easy
April 4, 2023
- Health Minister Vows Transparency in Vaccine Purchase after Audit Report
April 4, 2023
- 5 Otsuka Execs Earn 100 Million-Plus Pay in 2022: Securities Filing
April 4, 2023
- Chugai’s Annual Pay Tops 12 Million Yen for 1st Time: Securities Report
April 4, 2023
- MHLW Issues Guidance on eConsent in Clinical Trials
April 4, 2023
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…